Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study
| Autor: | Y. Kubo, K. Uchida, D. Fujiwara, Michiari Okuda, H. Nakamura, Tomomi Konishi, Masaaki Korenaga, S. Yamashita, Yuhki Yamaguchi, Keisuke Hino, Kiwamu Okita |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Hepatitis C virus Gene Expression Hepacivirus Receptor Interferon alpha-beta Interferon alpha-2 medicine.disease_cause Antiviral Agents Polymerase Chain Reaction Peripheral blood mononuclear cell law.invention Interferon law Virology Humans Medicine Prospective Studies RNA Messenger Receptor Prospective cohort study Polymerase chain reaction Receptors Interferon Messenger RNA Hepatology business.industry Interferon-alpha Membrane Proteins Odds ratio Hepatitis C Chronic Middle Aged Recombinant Proteins Infectious Diseases Liver Immunology Leukocytes Mononuclear RNA Viral Female business medicine.drug |
| Zdroj: | Journal of Viral Hepatitis. 11:136-140 |
| ISSN: | 1365-2893 1352-0504 |
| Popis: | Summary. The type I interferon (IFN) receptor consists of at least two subunits, IFNAR1 and IFNAR2. We previously found a correlation between IFNAR1 and IFNAR2 expression in liver, and a correlation in IFNAR2 expression, but not in IFNAR1, between liver and peripheral blood mononuclear cells (PBMCs). The aim of this study was to prospectively assess whether IFNAR2 expression levels in PBMCs as well as in liver act as markers for predicting response to IFN therapy in chronic hepatitis C patients. Fifty-two Japanese patients with chronic hepatitis C, were enrolled. IFNAR2 mRNA was quantified using competitive polymerase chain reaction, in liver and PBMC specimens, and of the 52 patients assigned to receive a 6-month course of interferon-α therapy, 36 patients who received more than 300 million units of interferon were analysed. IFNAR2 mRNA expression levels were significantly higher in liver than in PBMCs in all 36 patients (P = 0.016). Seventeen sustained virologic responders showed lower pretreatment hepatitis C virus (HCV)-RNA levels (P = 0.017) in serum and higher pretreatment levels of IFNAR2 mRNA in liver (P = 0.007), but not in PBMCs, compared with nonsustained virologic responders. In multivariate analysis, these factors were independently associated with a sustained virologic response (i.e. HCV-RNA level: odds ratio 0.23, 95% CI 0.038–0.864; and IFNAR2 in liver: odds ratio 1.116, 95% CI 1.015–1.227). Hence, IFNAR2 expression levels in liver, but not in PBMCs, is predictive of response to IFN treatment in chronic hepatitis C patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|